Upstream Bio reported collaboration revenue of $0.40 million and a net loss of $41.2 million for the third quarter of 2026, as the clinical-stage biotech prepares to transition into late-stage development. Management reaffirmed its timeline for pivotal trials and expects its current cash position of $207.4 million to support operations into 2028.

Key Highlights

  • Confirmed the planned initiation of Phase 3 clinical trials for lead candidate verekitug in both severe asthma and CRSwNP for the first quarter of 2027.
  • Cash, cash equivalents, and short-term investments of $207.4 million are projected to provide a sufficient liquidity runway through the end of 2027.
  • Research and development expenses increased 11% year-over-year to $36.6 million, driven by clinical costs for verekitug and personnel expansion.
  • Enrollment was completed for the Phase 2 VENTURE trial in COPD, with topline data readout anticipated in the second half of 2027.